伴随诊断合作与授权协议（2010-2025）

伴随诊断合作与许可协议报告全面深入地分析了全球领先的生物製药公司签署的伴随诊断协议，并提供前所未有的查阅途径。

这份经过全面修订和更新的报告详细介绍了2010年至2025年间的伴随诊断协议。

本报告深入分析了企业签订伴随诊断协议的原因和方式。这些协议通常涵盖多个方面，从合作研发到成果商业化。

本报告涵盖合作、开发、研究和授权等内容。

本报告包​​含自2010年以来公布的545项伴随诊断协议的完整清单，其中包括可用的财务条款以及各方披露的实际伴随诊断合作协议的在线记录链接。此外，在条件允许的情况下，记录还包括公司及其合作伙伴向美国证券交易委员会提交的合约文件。

本报告的引言概述了伴随诊断交易。

第一章概述了本报告。

第二章概述了自 2010 年以来伴随诊断交易活动。

第三章概述了自 2010 年以来主要的伴随诊断交易，并依交易额列出。

第四章提供了伴随诊断交易中最活跃的 25 家公司的完整列表，并附有简要概述，随后提供了伴随诊断交易和公开合约文件的完整列表。

第五章对自 2010 年 1 月以来签署和宣布的、合约文件公开的伴随诊断交易进行了全面深入的审查。

第六章对自2010年1月以来签署和公布的伴随诊断合作协议进行了全面深入的回顾。本章依具体的伴随诊断技术类型进行组织。

报告还包含大量表格和图表，展示了自2010年以来伴随诊断交易的趋势和活动。

此外，我们还提供了一个全面的协议目录，依公司名称（A-Z）、协议类型和治疗靶点进行分类。每个协议标题都透过网路连结指向线上协议记录，并在可用的情况下指向协议文件，以便根据需要轻鬆存取每个协议文件。

主要优势

伴随诊断合作开发和授权协议分析报告为读者提供以下主要优势：

• 了解自 2010 年以来的交易趋势
• 浏览伴随诊断合作与授权协议
• 基准分析 - 确定交易市场价值
• 财务条款 - 初始费用、里程碑付款、特许权使用费
• 依公司（A-Z）、交易类型和治疗领域分类的交易目录
• 以价值排名的主要交易
• 最活跃的交易撮合者
• 确定每笔交易的资产和条款
• 存取合约文件 - 深入了解交易结构
• 尽职调查 - 评估拟议交易条款对合作伙伴公司的适用性
• 节省数百小时的研究时间

范围

• 伴随诊断合作和许可协议报告是旨在帮助读者深入了解伴随诊断的发展趋势以及全球主要生物製药公司签订的协议结构。

伴随诊断的合作与授权协议包括：

• 生物製药产业伴随诊断交易趋势
• 製药和生物技术公司伴随诊断协议记录目录
• 依价值划分的主要伴随诊断协议
• 最活跃的伴随诊断许可协议公司
• 伴随诊断的合作与许可协议提供对可用协议记录的全面访问，包括合约文件（如有）。

分析协议有助于对以下方面进行尽职调查：

• 协议具体授予或选择哪些权利？
• 协议实际授予合作伙伴哪些权利？
• 授予了哪些排他性权利？
• 交易的付款结构是什么？
• 销售和付款如何审计？
• 合约期限是多久？
• 合约的关键条款是如何定义的？
• 智慧财产权（IPR）如何处理归属于谁？
• 谁负责商业化？
• 谁负责开发、供应和生产？
• 如何管理保密性和资讯揭露？
• 如何解决争议？
• 合约在什么情况下可以终止？
• 如果所有权发生变更，会发生什么事？
• 如何约定转让许可和分包条款？
• 贵公司要求使用哪些标准条款？
• 哪些标准条款会因交易对手和交易类型而异？
• 贵公司必须在哪个司法管辖区管辖其合约？

目录

摘要整理

第一章：引言

第二章：伴随诊断交易趋势

• 引言
• 伴随诊断交易历年回顾
• 最活跃的伴随诊断经销商
• 依交易类型划分的伴随诊断交易
• 依治疗领域划分的伴随诊断交易
• 依行业划分的伴随诊断交易
• 伴随诊断交易条款
  • 伴随诊断交易的关键价值因素
  • 伴随诊断合约的预付款
  • 伴随诊断交易的里程碑付款
  • 伴随诊断特许权使用费价格

第三章 - 主要伴随诊断交易

• 引言
• 以价值排名的顶级伴随诊断交易

第四章 - 最活跃的伴随诊断交易商

• 引言
• 最活跃的伴随诊断经销商
• 最活跃伴随诊断交易的公司简介

第五章 - 伴随诊断合约交易目录

• 引言
• 伴随诊断合约交易目录

第六章 - 依技术类型划分的伴随诊断交易

• 交易目录
• 交易目录 - 依公司划分的伴随诊断交易 (AZ)
• 交易目录- 依交易类型分类的伴随诊断交易
• 交易目录 - 依治疗领域分类的伴随诊断交易
• 交易类型定义
• 关于研究公司
• 当前合作伙伴
• 当前合约
• 依目前合作伙伴分类的最新报告标题

Companion Diagnostic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the companion diagnostic deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of companion diagnostic deals from 2010 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter companion diagnostic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 545 companion diagnostic deals announced since 2010 including financial terms where available including links to online deal records of actual companion diagnostic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of companion diagnostic dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in companion diagnostic dealmaking since 2010.

Chapter 3 provides an overview of the leading companion diagnostic deals since 2010. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in companion diagnostic dealmaking with a brief summary followed by a comprehensive listing of companion diagnostic deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of companion diagnostic deals signed and announced since Jan 2010, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of companion diagnostic partnering deals signed and announced since Jan 2010. The chapter is organized by specific companion diagnostic technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in companion diagnostic deal making since 2010.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Companion Diagnostic Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2010
• Browse companion diagnostic collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Companion Diagnostic Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of companion diagnostic trends and structure of deals entered into by leading biopharma companies worldwide.

Companion Diagnostic Collaboration and Licensing Deals includes:

• Trends in companion diagnostic dealmaking in the biopharma industry
• Directory of companion diagnostic deal records covering pharmaceutical and biotechnology
• The leading companion diagnostic deals by value
• Most active companion diagnostic licensing dealmakers
• Companion Diagnostic Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in companion diagnostic dealmaking

• 2.1. Introduction
• 2.2. Companion diagnostic deals over the years
• 2.3. Most active companion diagnostic dealmakers
• 2.4. Companion diagnostic deals by deal type
• 2.5. Companion diagnostic deals by therapy area
• 2.6. Companion diagnostic deals by industry sector
• 2.7. Deal terms for companion diagnostic deals
  • 2.7.1 Companion diagnostic deals headline values
  • 2.7.2 Companion diagnostic deal upfront payments
  • 2.7.3 Companion diagnostic deal milestone payments
  • 2.7.4 Companion diagnostic royalty rates

Chapter 3 - Leading companion diagnostic deals

• 3.1. Introduction
• 3.2. Top companion diagnostic deals by value

Chapter 4 - Most active companion diagnostic dealmakers

• 4.1. Introduction
• 4.2. Most active companion diagnostic dealmakers
• 4.3. Most active companion diagnostic deals company profiles

Chapter 5 - Companion diagnostic contracts dealmaking directory

• 5.1. Introduction
• 5.2. Companion diagnostic contracts dealmaking directory

Chapter 6 - Companion diagnostic dealmaking by technology type

• Deal directory
• Deal directory - Companion diagnostic deals by company A-Z
• Deal directory - Companion diagnostic deals by deal type
• Deal directory - Companion diagnostic deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Companion diagnostic deals since 2016
• Figure 2: Active companion diagnostic dealmaking activity - 2016 - 2025
• Figure 3: Companion diagnostic deals by deal type since 2016
• Figure 4: Companion diagnostic deals by therapy area since 2016
• Figure 5: Companion diagnostic deals by industry sector since 2016
• Figure 6: Companion diagnostic deals with a headline value
• Figure 7: Companion diagnostic deals with an upfront value
• Figure 8: Companion diagnostic deals with a milestone value
• Figure 9: Companion diagnostic deals with a royalty rate value
• Figure 10: Top companion diagnostic deals by value since 2016
• Figure 11: Most active companion diagnostic dealmakers 2016 - 2025
• Figure 12: Companion diagnostic deals by technology type since 2016